APLS vs. BBIO, OGN, IONS, MDGL, ALPN, NUVL, CYTK, ALKS, PRGO, and BPMC
Should you be buying Apellis Pharmaceuticals stock or one of its competitors? The main competitors of Apellis Pharmaceuticals include BridgeBio Pharma (BBIO), Organon & Co. (OGN), Ionis Pharmaceuticals (IONS), Madrigal Pharmaceuticals (MDGL), Alpine Immune Sciences (ALPN), Nuvalent (NUVL), Cytokinetics (CYTK), Alkermes (ALKS), Perrigo (PRGO), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical preparations" industry.
BridgeBio Pharma (NASDAQ:BBIO) and Apellis Pharmaceuticals (NASDAQ:APLS) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends, community ranking and institutional ownership.
99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. 28.5% of BridgeBio Pharma shares are owned by insiders. Comparatively, 7.5% of Apellis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Apellis Pharmaceuticals has a net margin of -79.67% compared to Apellis Pharmaceuticals' net margin of -246.24%. Apellis Pharmaceuticals' return on equity of 0.00% beat BridgeBio Pharma's return on equity.
Apellis Pharmaceuticals received 177 more outperform votes than BridgeBio Pharma when rated by MarketBeat users. However, 67.63% of users gave BridgeBio Pharma an outperform vote while only 67.45% of users gave Apellis Pharmaceuticals an outperform vote.
BridgeBio Pharma has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.
BridgeBio Pharma presently has a consensus price target of $48.00, suggesting a potential upside of 59.52%. Apellis Pharmaceuticals has a consensus price target of $76.67, suggesting a potential upside of 85.59%. Given BridgeBio Pharma's higher possible upside, analysts plainly believe Apellis Pharmaceuticals is more favorable than BridgeBio Pharma.
Apellis Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, Apellis Pharmaceuticals had 10 more articles in the media than BridgeBio Pharma. MarketBeat recorded 26 mentions for Apellis Pharmaceuticals and 16 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.91 beat Apellis Pharmaceuticals' score of 0.61 indicating that Apellis Pharmaceuticals is being referred to more favorably in the news media.
Summary
BridgeBio Pharma and Apellis Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.
Get Apellis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apellis Pharmaceuticals Competitors List
Related Companies and Tools
